The Neural Gut–Brain Axis of Pathological Protein Aggregation in Parkinson’s Disease and Its Counterpart in Peroral Prion Infections by Beekes, Michael
viruses
Review
The Neural Gut–Brain Axis of Pathological Protein Aggregation





Citation: Beekes, M. The Neural
Gut–Brain Axis of Pathological
Protein Aggregation in Parkinson’s
Disease and Its Counterpart in




E. Kincaid and Jason C. Bartz
Received: 15 June 2021
Accepted: 14 July 2021
Published: 18 July 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the author.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
Prion and Prionoid Research Unit, ZBS 6-Proteomics and Spectroscopy, ZBS-Centre for Biological Threats and
Special Pathogens, Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany; beekesm@rki.de;
Tel.: +49-30-18754-2396
Abstract: A neuropathological hallmark of Parkinson’s disease (PD) is the cerebral deposition of
abnormally aggregated α-synuclein (αSyn). PD-associated αSyn (αSynPD) aggregates are assumed to
act, in a prion-like manner, as proteinaceous nuclei (“seeds”) capable of self-templated propagation.
Braak and colleagues put forward the idea of a neural gut-brain axis mediating the centripetal spread
of αSynPD pathology from the enteric nervous system (ENS) to the brain in PD. This has sparked
great interest and initiated passionate discussions both in support of and opposing the suggested
hypothesis. A precedent for the spread of protein seeds or seeding from the gastro-intestinal (GI)
tract to the central nervous system (CNS) had been previously revealed for pathological prion protein
in peroral prion infections. This article scrutinizes the similarities and dissimilarities between the
pathophysiological spread of disease-associated protein aggregation along the neural gut–brain axis
in peroral prion infections and PD. On this basis, evidence supporting the proposed neural gut–brain
axis in PD is concluded to be not as robust as that established for peroral prion infections. New tools
for the ultrasensitive detection of αSynPD-associated seeding activity in archived or fresh human
tissue samples such as real-time quaking induced conversion (RT-QuIC) or protein misfolding cyclic
amplification (PMCA) assays can possibly help to address this deficit in the future.
Keywords: Parkinson’s disease; peroral prion infections; alpha-synuclein; prion protein; seeds;
spread; enteric nervous system; vagus nerve
1. Introduction
The deposition of misfolded and aggregated alpha-synuclein (αSyn) in cerebral neu-
ronal cell bodies or processes (referred to as Lewy bodies [LB] or Lewy neurites [LN],
respectively [1]) and associated with synapses [2] is a neuropathological hallmark of idio-
pathic Parkinson’s disease (abbreviated in the following simply as PD, since other forms of
Parkinson’s disease will not be addressed in this review). Pathological αSyn species of PD
(αSynPD) are assumed to act as proteinaceous nuclei (“seeds”) which recruit endogenous
cellular or post-translationally modified αSyn and integrate it into their own misfolded
oligomeric or polymeric aggregate structure. The seeding activity of αSynPD is thought to
mediate, in a process of nucleation-dependent aggregation [3], self-templated propagation
of the pathological protein state [4–6] (Figure 1).
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Figure 1. Mechanistic model of nucleation-dependent protein aggregation thought to underly the self-assembly and prop-
agation of pathological αSynPD, PrPTSE or other proteinaceous seeds in PD, TSE and further neurodegenerative protein 
aggregation diseases, respectively. Under certain conditions, (usually monomeric) protein conformers can spontaneously, 
or driven by genetic factors, assemble into β-sheet-rich aggregates that constitute self-replicative protein particles, or seeds. 
Such initial seed formation, referred to as primary nucleation, is controlled by a high kinetic barrier. Primary nucleation 
is exemplarily depicted for hamster PrP, schematically showing the aggregation of PrP monomers (1, [7]) into a PrPTSE 
seed (2, [8]). Once proteinaceous seeds have been endogenously formed, or exogenously entered the organism, they can 
swiftly recruit and attach further monomers of their constitutive proteins. In this process of elongation, new aggregate 
mass is generated by the attachment of monomeric species to the ends of the seeding-active particles. Additionally, sec-
ondary nucleation may occur by the formation of new nucleation sites on the particle surface. When protein particles with 
primary or secondary nucleation sites fragment into smaller aggregates, progeny seeds enter the replication cycle and 
further propagate the pathological protein state. The figure was produced, with modifications, following a previously 
published template [4] in consideration of Meisl et al. [9]. Credits for mounted image components: (1) 
https://www.rcsb.org/structure/4YXL: crystal structure of Syrian hamster prion protein complexed with POM1 FAB is 
licensed under the PDB Privacy and Usage Policy, and (2) https://www.biorxiv.org/content/10.1101/2021.02.14.431014v2: 
structure of an infectious mammalian prion is licensed under the Creative Commons CC0 1.0 Universal (CC0 1.0) Public 
Domain Dedication. 
Pathological accumulation of αSynPD in the brain is accompanied by a progressive 
loss of dopaminergic neurons in the substantia nigra pars compacta, causing a reduction 
of the neurotransmitter dopamine and thereby affecting neurological feedback loops in 
the basal ganglia. This results in the manifestation of PD-typical motor deficits such as 
tremor, bradykinesia, rigor and postural instability [10].  
However, αSynPD aggregates do not exclusively occur in the central nervous system 
(CNS) but have been detected, too, in the enteric nervous system (ENS) of the gastro-in-
testinal (GI) tract of PD patients. Concomitantly with this, PD is associated with non-mo-
tor symptoms that often manifest prodromally in the GI tract, e.g., in the form of consti-
pation or reduced peristalsis [11]. This gave rise to hypothesize both a link between clini-
cal PD manifestations in the GI tract and brain, and αSynPD pathologies in these tissues as 
a cause for these disease symptoms [12,13]. The idea of a gut–brain axis in PD was put 
forward by Braak and colleagues who in 2003 had presented a staging system for PD ac-
cording to identified patterns of αSynPD deposition in autopsy cases [14]. Based on this 
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propagation of pathological αSynPD, PrPTSE or other proteinaceous seeds in PD, TSE and further neurodegenerative protein
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Pathological accumulation of αSynPD in the brain is accompanied by a progressive
loss of dopaminergic neurons in the substantia nigra pars compacta, causing a reduction of
the neurotransmitter dopamine and thereby affecting neurological feedback loops in the
basal ganglia. This results in the manifestation of PD-typical motor deficits such as tremor,
bradykinesia, rigor and postural instability [10].
However, αSynPD aggregates do not exclusively occur in the central nervous system
(CNS) but have been detected, too, in the enteric nervous system (ENS) of the gastro-
intestinal (GI) tract of PD patients. Concomita tly with this, PD is associated with non-
motor symptoms that often manifest prodromally in the GI tract, e.g., in the form of
constipation o reduced peristalsis [11]. This gave rise to hypothesize both a link between
clinical PD manifestations in the GI tract and brain, and αSynPD p thologies in these issues
as a cause for these disease symptoms [12,13]. The idea of a gut–brain axis in PD was
put forward by Braak and colleagues who in 2003 had presented a staging system for PD
according to identified patterns of αSynPD deposition in autopsy cases [14]. Based on this
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staging system they proposed that a pathogen, first considered as a neurotropic virus and
later increasingly emphasized as misfolded and aggregated αSyn with prion-like properties,
propagates from initial foci in the ENS retrogradely via efferent fibres of the vagus nerve to
the dorsal motor nucleus of the vagus nerve (DMV, elsewhere also abbreviated as DMNV)
in the brain stem, and from there further on to other cerebral target sites including the
substantia nigra [15]. Together with a second proposed spreading pathway for αSynPD
pathology, from the nasal cavity via the olfactory bulb into the temporal lobe, the concept
became known as the dual-hit hypothesis of PD [16,17].
A precedent for a vagal gut–brain axis mediating brain invasion by proteinaceous
seeds or seeding from the GI tract had been revealed for peroral prion infections several
years before Braak and colleagues presented their concept. Prions are infectious self-
replicating protein seeds that are thought to essentially consist of pathologically misfolded
and aggregated conformational isomers of the cellular prion protein (PrPC), referred to
as PrPSc or PrPTSE [18,19]. They are the causative agents of transmissible spongiform
encephalopathies (TSE), such as scrapie, bovine spongiform encephalopathy (BSE), chronic
wasting disease (CWD) or Creutzfeldt–Jakob disease (CJD) and its BSE-derived variant
(vCJD) [20].
The putative spread of aSynPD pathology along the gut–brain axis and within the
brain in PD, as well as the potentially prion-like properties of αSynPD seeds and their
disputed role as a driver of clinical disease, have been summarized and discussed in
numerous scientific articles and reviews over the past years [21–28]. However, only rarely
and then mostly summarily has reference been made to the available original data and
reports on the actual spread of prions along the gut–brain axis in peroral prion infections.
This can be traced back even to the roots of the concept of a gut–brain axis in PD. Already,
Braak and colleagues only indirectly and rudimentarily quoted the original findings on
the propagation of prions along the gut–brain axis in peroral TSE infections that provided
an obvious blueprint for their spreading model, particularly with regard to the retrograde
axonal routing along the vagus nerve from the ENS to the DMV [15].
Such omission does not seem helpful for an optimal comparative evaluation of the
available data on the spread of PrPTSE and αSynPD pathologies along the gut–brain axis in
peroral prion infections and PD, respectively. In one of the few papers that include original
literature on the gut–brain axis in peroral prion infections in somewhat more detail, the
authors state “An important research goal is to elucidate the degree of similarity between
pathophysiological processes in PD and those of true prion disease” [29]. In line with this
approach, this article intends to provide a review of neural pathways along the gut–brain
axis thought to mediate centripetal spread of PrPTSE and αSynPD seeds or seeding from the
alimentary tract to the CNS. Key findings obtained in this regard for authentic mammalian
prions and PrPTSE will be summarized and compared with available data on PD-associated
αSyn forms. On this basis, similarities, dissimilarities, outstanding questions and possible
future research directions will be highlighted. This review does not include findings on
pathological αSyn species from non-PD αSyn aggregation diseases (e.g., dementia with
Lewy bodies [DLB] or multiple system atrophy [MSA]), or on in vitro generated fibrillar or
non-fibrillar αSyn assemblies, because such αSyn species may not necessarily share the
pathophysiological properties of αSynPD with respect to the hypothetized gut–brain axis
in PD.
2. The Established Neural Gut–Brain Axis in Peroral Prion Infections
Early evidence for a centripetal spread of prion infection from the GI tract to the
spinal cord via components of the enteric and autonomic nervous system was obtained in
infectivity studies with mice that had been intragastrically challenged with scrapie [30].
The dynamics of the spread of perorally acquired prion infections from the GI tract to
the spinal cord and brain were subsequently further elucidated in hamsters perorally
exposed to the 263 K scrapie agent [31–36]. These studies used bioassays in animals for
the detection of prion infectivity, as well as different techniques for the visualization of
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PrPTSE, which was established in many studies as a reliable biochemical marker for TSE
infectivity [31,33,37–41], to map the temporal–spatial spread of infection after a peroral
challenge with prions. Throughout this review, the abbreviation PrPTSE will be used to
collectively designate pathological forms of PrP associated with prion infection that can
be detected in affected animals and humans by analytical methods such as immunohisto-
chemistry (IHC) [32,42], Western blotting [31,43] or paraffin-embedded tissue blotting [44].
Western and paraffin-embedded tissue blotting detect partially proteinase K (PK)-resistant
forms of PrPTSE, while IHC visualizes aggregated deposits of this protein.
Studies using the hamster model of peroral 263 K scrapie infection revealed, among
other findings, that initial foci of PrPTSE deposition in the nervous system—and thus
neuroinvasion—occurred in submucosal and myenteric ENS ganglia of the small intes-
tine [32,34]. The small intestine (as with other parts of the gut and the stomach) is inner-
vated, partly via ENS ganglia, by the vagus and splanchnic nerves, efferent fibres of which
belong to the parasympathetic and sympathetic nervous system, respectively. This consti-
tutes a dual neural gut–brain axis, along which the infection was conveyed directly or via
the spinal cord, respectively, to the brain [32,33,35,36]. Low levels of prion infectivity could
be directly detected in the cervical vagus nerve of clinically diseased hamsters perorally
challenged with 263 K scrapie [32]. That the vagus nerve can harbour PrPTSE had already
previously been found in hamsters intraperitoneally challenged with scrapie [45]. While
these findings indicated the vagus nerve as a conduit for prion infectivity or PrPTSE, taken
in themselves, they did not provide information on the direction of spread.
However, as reviewed in detail elsewhere [46], the centripetal spread of perorally
acquired 263 K scrapie infection in hamsters was progressively deciphered [31–36], and
revealed to ascend retrogradely via efferent fibres of the vagus and splanchnic nerves
innervating the gut, to the DMV and commissural nucleus of the solitary tract in the
medualla oblongata of the brain, and to the celiac/mesenteric ganglion complex and
intermediolateral cell column (IML) in the thoracic spinal cord, respectively. In this context,
it is noteworthy that the time window for the detection of PrPTSE pathology in the ENS only
was obviously so narrow that it could not be hit in the hamster model. The ENS and DMV
of hamsters that had been perorally challenged with identical doses of 263 K scrapie prions
were still found to be immunohistochemically negative for PrPTSE at 45 and 56 days post
infection (dpi), respectively, while both sites became practically simultaneously positive
for PrPTSE at 62/63 in two out of four (2/4) animals and at 60 dpi in 2/6 animals [32,47].
From the sites of cerebral and spinal neuroinvasion, the infection propagated, apparently
along defined neuroanatomical projections and in a specific temporal–spatial sequence,
within the brain and spinal cord [35]. In the latter, infection showed a bidirectional spread
that included ascension to the brain. Centrifugal routing from the CNS appeared to be
responsible for subsequent infection of sensory nodose and dorsal root ganglia of the vagus
and splanchnic nerve circuitries, respectively, although a direct spread from the viscera
along sensory fibres to the nodose and dorsal root ganglia could not be ruled out [32].
Detailed pictorial representations summarizing these findings on the spread of infection
along the gut–CNS axis in hamsters perorally infected with scrapie have been provided by
McBride et al. [32] or elsewhere [48].
Mostly identical or at least largely similar findings have been reported regarding
the centripetal spread of prions from ENS ganglia to the brain and spinal cord via the
vagus nerve circuitry (DMV of the vagus nerve–commissural nucleus of the solitary
tract–nodose ganglia) and splanchnic nerve circuitry (celiac and mesenteric ganglion
complex–IML–dorsal root ganglia), respectively, in perorally/alimentarily acquired scrapie
of sheep [49–51], CWD of cervids [52,53], and BSE of cattle [54].
In light of additionally reported findings, some further refinements were made to the
dual gut–brain spreading model of peroral prion infections. These include the identification
of the sympathetic ganglia chain in cattle perorally challenged with BSE as an additional
spreading pathway bypassing the spinal cord and mediating infection of the obex and
DMV beside the vagus nerve [55]. In this study, it became evident again that, if at all, only a
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very narrow time window existed in which PrPTSE pathology was already detectable in the
ENS but not yet in the brain. Of eight animals whose ENS and brainstem were examined
between 16 and 28 months post infection, only one was found to be affected in the ENS
without detectable PrPTSE or infectivity in the obex or caudal medulla, respectively.
After foodborne infection of non-human primates (cynomolgus monkeys) with BSE
prions, early infection of ENS ganglia was observed, but indications for brain invasion
via the vagus nerve as typically seen in peroral prion infections of rodents and ruminants
were found in only one monkey. In contrast, most macaques showed invasion of the
CNS primarily at the level of the lumbar spinal cord, which was obviously mediated by
anterograde spread along visceral afferents. PrPTSE accumulation in dorsal root ganglia
preceded PrPTSE deposition in the corresponding dorsal horn, with initial accumulations
in the substantia gelatinosa [56].
In vCJD patients, i.e., humans that acquired the infection presumably due to an
alimentary exposure to BSE prions, PrPTSE was found in sympathetic celiac, superior
mesenteric and stellate ganglia [57], as well as in dorsal root ganglia [58]. This supported a
role for the sympathetic nervous system in prion propagation from the gut to the CNS. In
one study on the neuropathology of vCJD, ENS ganglia and parasympathetic structures
also showed positive imunohistochemical staining, but the author stressed that these
findings need to be interpreted with caution [58].
Additionally to the described centripetal and centrifugal spreading pathways of the
autonomic and peripheral sensory nervous system, the neural routing of TSE agents in
peroral prion infections includes further aspects such as centrifugal spread from the CNS
to muscles [59,60] and skin [61]. Furthermore, peroral TSE infections may also result in a
blood-borne dissemination of prions from the periphery to the brain, as will be outlined in
the following paragraph.
3. Haematogenous Neuroinvasion of the Brain in Peroral Prion Infections
Comprehensive studies in scrapie- or BSE-infected sheep that included peroral in-
fections have shown that the haematogenous route can represent a parallel or alternative
pathway to cerebral neuroinvasion from the ENS via the autonomic nervous system [62].
Access of prions to the bloodstream after ingestion of TSE agents is thought to occur fol-
lowing invasion of and replication in components of the gut-associated lymphoid tissue
(GALT), possibly among other pathways, via infected free-ranging lymphoid cells that
cross to the efferent lymph in the cortical and paracortical sinuses of GALT-draining lymph
nodes [46].
In cases of haematogenous prion spread, initial PrPTSE accumulation also consistently
occurred in the DMV and its related circumventricular organ with a diminished blood–
brain barrier (i.e., the area postrema) [63]. Therefore, special attention had to be paid to the
presence or absence of pathological protein aggregates in circumventricular organs when
interpreting findings of PrPTSE pathologies in the DMV in tracing studies. Experiments in
hamsters on the neural gut–brain axis in peroral 263 K scrapie infections did not reveal any
evidence for haematogenous spread of infection to the brain. PrPTSE was not detected early
in infection at sites with an impaired blood–brain barrier, such as the area postrema [35] or
the choroid plexus [32]. In addition, routing via the blood would not be consistent with the
observed temporal–spatial pattern of PrPTSE targeting in the autonomic nervous system,
spinal cord and brain [32].
4. The Postulated Neural Gut–Brain Axis in Parkinson’s Disease (PD)
Starting in 2003, Braak and colleagues reported a pathological staging system for
PD, which was based on an identified temporal–spatial pattern of LB and LN pathology
that could be apparently well aligned with the course of the disease [14,64]. The authors
reported that cerebral Lewy pathology (LP) in PD initially occurs in the olfactory bulb and
the DMV before propagating to other cerebral areas including the substantia nigra [14,15,64].
Their findings led Braak and colleagues to propose the “dual-hit” hypothesis postulating
Viruses 2021, 13, 1394 6 of 17
that sporadic PD starts at two sites in the body, i.e., neurons of the nasal cavity and neurons
of the ENS in the gut or stomach, due to exposure to an unknown neurotophic pathogen
triggering LP [15–17]. From these sites, the LP stimulating agent was hypothesized to
invade the brain in a specific temporal–spatial pattern, i.e., anterogradely along the olfactory
tract to the temporal lobe and retrogradely along the vagus nerve to the DMV, respectively.
Braak and colleagues reasoned that the hypothesized neurotropic pathogen could
possibly induce conformational changes in normal αSyn molecules provoking their aggre-
gation without becoming itself aggregated and integrated into the pathological αSynPD de-
posits, or that the pathogen could possess unconventional prion-like properties and might
consist of misfolded αSyn fragments [15]. The implication of a prion-like self-templated
propagation of the pathological protein states in PD, together with the additional finding
that pathological αSynPD aggregates can spread from neuron to neuron [65–68] delivered a
plausible mechanistic basis for the proposed stereotypic temporal–spatial spread of αSyn
pathology in PD.
Once self-propagating αSynPD aggregates, or seeds, have been formed in such a
scenario in olfactory and enteric neurons, αSynPD pathology further propagates in the
nervous system by the spread of αSyn seeding (that may or may not include a translocation
of αSyn seeds) in highly defined temporal–spatial patterns, apparently trans-synaptically,
along established neuronal projections and circuits to the initial target areas in the brain.
It has been demonstrated in animal experiments that vagal axons and terminals from
preganglionic efferent neurons located in the DMV show immunoreactivity for αSyn, and
that the latter neurons have synaptic contacts with αSyn-positive neurons in the myenteric
plexus of both the stomach and duodenum [69]. This supports the vagus nerve as an αSyn-
expressing parasympathetic pathway for the retrograde propagation of αSyn pathology
from the ENS to the CNS.
LB and LN have also been detected in sympathetic preganglionic neurons in the IML
of the spinal cord, and in postganglionic neurons of the celiac ganglion in early stages
of PD [70–72]. Thus, an additional spreading pathway of αSyn pathology to the CNS is
conceivable by retrograde axonal propagation along the splanchnic nerve to postganglionic
sympathetic neurons in the prevertebral celiac ganglion. From there, invasion of the spinal
cord may occur via further retrograde spread to preganglionic sympathetic neurons in
the IML [73]. Klingelhoefer and Reichmann [74] concluded in a comprehensive review
paper on the topic that “Current evidence indicates that PD pathology that involves alpha-
synuclein propagates from the ENS by trans-synaptic cell-to-cell transmission through
sympathetic and parasympathetic nerves to the DMNV and IML into the CNS”. This seems
to suggest a nearly perfect cross-match with the spread of PrPTSE pathology along the dual
gut–brain axis in peroral prion infections. At first glance, such conclusion appears also
striking when looking at pictorial representations of the neural spreading pathways of
PrPTSE and αSynPD pathologies suggested to operate in peroral prion infections [32,48]
and PD [15,74,75], respectively (Figure 2). However, is this really how the facts are?




Figure 2. Pictorial representation of the neural gut–brain axis thought to be involved in the centripetal spread of patho-
logical protein aggregation from the intestine to the CNS in both peroral prion infections as well as PD. As established in 
great detail for perorally acquired TSE early spread of prions and PrPTSE pathology to the CNS occurs from ENS ganglia 
in a retrograde direction along parasympathetic and sympathetic efferents of the vagus and splanchnic nerves, to the DMV 
in the medulla oblongata and the IML in the spinal cord, respectively (reviewed in: [46,48]). A similar concept was subse-
quently proposed for the propagation of LP in PD from enteric ganglia in the gastrointestinal tract to the CNS, initially 
with respect to parasympathetic and later also with respect to sympathetic spreading pathways [14,73,76]. Dashed blue 
and red arrows indicate retrograde spread via efferent parasympathetic or sympathetic projections of the vagus or 
splanchnic nerves, respectively, for both peroral prion infections and PD. Dashed grey arrows mark spinal ascension of 
PrPTSE pathology or LP to the brain following invasion of the IML at thoracic spinal cord levels of splanchnic innervation 
[46,73]. The figure was produced, with modifications, following templates from McBride et al. [32] and Mabbott and Mac-
Pherson [48]. Credits for mounted image components: “Blausen 0838 Sympathetic Innervation” and “Blausen 0703 Para-
sympathetic Innervation” by Bruce Blaus are licensed under the Creative Commons Attribution 3.0 Unported License (CC 
BY 3.0); “Anatomic structure of enteric plexus” (image ID FK8KPF) is licensed by Alamy Limited (Abingdon, UK, invoice 
number IY01945617). AP, area postrema; CMG, celiac or mesenteric ganglion; DMV, dorsal motor nucleus of the vagus 
nerve; DRG, dorsal root ganglion; ENS, enteric nervous system; IML, intermediolateral cell column; L, border between 
thoracic and lumbar spinal cord; MO, medulla oblongata; NG, nodose ganglion; SN, splanchnic nerves; STN, solitary tract 
nucleus; T, border between cervical and thoracic spinal cord; VN, vagus nerve. 
5. Is There a Neural Gut–Brain Axis in PD? Pros, Cons and Insights from Peroral 
Prion Infections 
Before comparing the temporal–spatial spreading of PrPTSE and αSynPD pathologies, 
i.e., of the propagation of PrPTSE and αSynPD seeds or seeding, along the gut–brain axis in 
peroral prion infections and PD, respectively, fundamental differences with regard to the 
diseases must be pointed out. 
First, TSE can be transmitted and are partly even contagious (e.g., ovine scrapie or 
cervid CWD), whereas PD is generally assumed to be non-transmissible, at least not as a 
full-blown syndrome. Thus, while PD-associated αSynPD seeds share nucleation-depend-
ent protein aggregation as the molecular mechanism of their origin and propagation with 
PrPTSE seeds, they lack the latter’s obvious clinical infectiousness. Particularly, the role of 
LP-associated and other forms of αSynPD as a pathogenic driver of neuronal dysfunction, 
death of nerve cells and symptomatic disease is still less reliably established, and more 
controversially discussed, than that of PrPTSE for prion diseases.  
Figure 2. Pictorial representation of the neural gut–brain axis thought to be involved in the c ntripetal spread of pathological
protein aggregation from the intestine to the CNS in both peroral prion infections as well as PD. As established in great
detail for perorally acquired TSE early spread of prions and PrPTSE pathology to the CNS occurs from ENS ganglia in a
retrograde direction along parasympathetic and sympathetic efferents of the vagus and splanchnic nerves, to the DMV in the
medulla oblongata and the IML in the spinal cord, respectively (reviewed in: [46,48]). A similar concept was subsequently
proposed for the ropagation of LP in PD from enteric ganglia in the gastrointestinal tract to the CNS, initially with respect
to parasympathetic and later also with respect to sympathetic spreading pathways [14,73,76]. Dashed blue and red arrows
indicate retrograde spread via efferent parasympathetic or sympathetic projections of the vagus or splanchnic nerves,
respectively, for both peroral prion infections and PD. Dashed grey arrows mark spinal ascension of PrPTSE pathology or LP
to the brain following invasion of the IML at thoracic spinal cord levels of splanchnic innervation [46,73]. The figure was
produced, with modifications, following templates from McBride et al. [32] and Mabbott and MacPherson [48]. Credits for
mounted image components: “Blausen 0838 Sympathetic Innervation” and “Blausen 0703 Parasympathetic Innervati n” by
Bruce Blaus are licensed under the Creative Commons Attribution 3.0 Unp rted License (CC BY 3.0); “Anatomic structure
of enteric plexus” (image ID FK8KPF) is licensed by Alamy Li ited (Abingdon, UK, invoice number IY01945617). AP, area
postrema; CMG, celiac or mesenteric ganglion; DMV, dorsal motor nucleus of the vagus nerve; DRG, dorsal root ganglion;
ENS, enteric nervous system; IML, intermediolateral cell column; L, border between thoracic and lumbar spinal cord; MO,
medulla oblongata; NG, nodose ganglion; SN, splanchnic nerves; STN, solitary tract nucleus; T, border between cervical
and thoracic spinal cord; VN, vagus nerve.
5. Is There a Neural Gut–Brain Axis in PD? Pros, Cons and Insights from Peroral
Prion Infections
Before comparing the temporal–spatial spreading of PrPTSE and αSynPD pathologies,
i.e., of the propagation of PrPTSE and αSynPD seeds or seeding, along the gut–brain axis in
peroral prion infections and PD, respectively, fundamental differences with regard to the
diseases must be pointed out.
First, TSE can be transmitted and are partly even contagious (e.g., ovine scrapie or
cervid CWD), whereas PD is generally assumed to be non-transmissible, at least not as a full-
blown syndrome. Thus, while PD-associated αSynPD seeds share nucleation-dependent
protein aggregation as the molecular mechanism of their origin and propagation with
PrPTSE seeds, they lack the latter’s obvious clinical infectiousness. Particularly, the role of
LP-associated and other forms of αSynPD as a pathogenic driver of neuronal dysfunction,
death of nerve cells and symptomatic disease is still less reliably established, and more
controversially discussed, than that of PrPTSE for prion diseases.
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Second, when comparing the spread of PrPTSE and αSynPD pathology along the gut–
brain axis, a further discrepancy needs to be considered. For the mapping of spreading
patterns in peroral prion infections PrPTSE itself was used as a tracer. In contrast, the
concept of the gut–brain axis in PD was derived less from an analysis of αSynPD pathology
as a whole, but mainly based on the detection of LB and LN. However, several different
studies have demonstrated that neuritic αSyn pathology is much more abundant than
perikaryal inclusions in different αSyn aggregation diseases [77–79], and up to 90% or
even more of pathological cerebral αSyn aggregates were found to not be localized in LB
or LN but at presynapses in the form of much smaller micro-deposits [2,80]. This raises
the fundamental question as to whether the spread of αSynPD seeds or seeding along the
gut–brain axis in PD can be reliably concluded from identified patterns of LP.
The assumption of an ascending vagal pathway conveying brain invasion of αSynPD
pathology from the ENS is based on the following factors according to the essence of
Braak’s concept: (i) that the DMV is an initial site of αSynPD pathology in the brain, (ii) that
αSynPD pathology in the ENS should basically precede that in the DMV, and (iii) that the
vagus nerve can contain and act as a conduit for αSynPD.
5.1. Studies Based on Human Tissues and Epidemiological Data
Braak and colleagues derived their concept from the postmortem examination of
deceased humans. Therefore, they could not draw on definite longitudinal information,
i.e., hard data on the evolution of LP as a function of time. This represents a noteworthy
difference to the highly controlled cause-effect studies in animals that elucidated the neural
gut–brain axis of PrPTSE propagation in peroral prion infections. Rather, longitudinal
relationships had to be inductively concluded by Braak and colleagues on the basis of
plausible but partly unverified assumptions. This could provide an explanation for the fact
that subsequent studies delivered differing results in that only about half of the examined
PD patients were found to show patterns of LP that were consistent with Braak’s staging
system [81–83], with some patients having been apparently free of detectable LP [84].
Attems and Jellinger reported based on the examination of 60 cases that about 18% did
not follow the Braak staging scheme, and that in about 8%, the DMV was not involved
despite definite aSyn inclusions in other brainstem or even cortical regions [85]. That
the DMV was not displaying LP in some cases led these authors to the conclusion that it
is not an obligatory transfer or trigger site in PD. Further reports in support or against
Braak’s staging hypothesis for PD have been recently reviewed by Jellinger [86] with the
conclusion that the validity of this staging concept warrants further studies in regard to
various subtypes of PD.
Apparently more critical with respect to Braak’s hypothesis is that comprehensive
postmortem studies could not confirm its interpretation of the relative prevalence, and
thus the implied temporal sequence, of αSynPD pathology in the ENS and brain. Beach and
colleagues [27,87] reported, that they “did not find a single case in which LB and LN were
present in the peripheral autonomic networks (including the ENS) but not in the CNS” in a
neuropathological survey of 417 autopsy cases. After these authors had expanded their
data collection based on more than 600 whole-body autopsies, they still failed to identify a
case in which the ENS or other parts of the peripheral nervous, but not the brain, exhibited
LP [27].
However, as pointed out by Borghammer and Van Den Berge [88], the time window
for the identification of αSynPD pathology in the ENS without involvement of the brain
stem may be quite narrow and possibly comprises only a few weeks. As these authors
stated, “initially highly localized gut pathology could immediately propagate to the DMV,
giving rise to the first CNS pathology, and thereby disqualifying this patient from being
categorized as a gut-only case”. Finding individuals with gut-only αSynPD pathology
could therefore be difficult. In light of similar findings described above for peroral prion
infections in hamsters and cattle, this seems to be a valid point. However, as long as the
lack of human gut-only cases highlighted by Beach and colleagues [27] is not eliminated
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or compensated by other findings conclusively proving Braak’s postulated sequence of
events, there basically remain at least three logical alternatives: (i) αSynPD pathology in PD
starts simultaneously at different sites of the nervous system (e.g., in the ENS and DMV),
(ii) αSynPD pathology in the ENS precedes that in the brain, or (iii) αSynPD pathology in
the brain predates that in the ENS. This would also leave it uncertain as to whether αSynPD
pathology spreads along the vagus nerve centripetally, centrifugally, bi-directionally or
at all.
While phosphorylated αSynPD histopathology had been detected in the vagus nerve
of PD patients [89], the involvement of the vagus nerve in the development of PD was
further examined in two studies that analyzed the effect of full truncal vagotomy (per-
formed in patients for the treatment of peptic ulcer) on the risk of developing the disease.
Statistical analyses using data from Danish registries indicated that full truncal vagotomy
was associated with a decreased risk for subsequent development of PD, suggesting that
the vagus nerve may be critically involved in PD pathogenesis [90]. Similarly, a study based
on nationwide Swedish registers found suggestive evidence for a potential protective effect
of truncal vagotomy against PD development [91]. However, when the Danish dataset was
independently reanalyzed by a Norwegian research group with different patient catego-
rization and methods for statistical analysis, these authors came to the conclusion “that it
remains to be shown that vagotomy reduces the risk of having PD” [92].
Drawing definitive conclusions from these epidemiological studies is additionally
complicated by a possible secondary effect of vagotomy, i.e., retrograde degeneration of
neurons in the DMV [93–95]. Considering the observed haematogenous spread of prions
to the DMV described above for specific paradigms of perorally acquired TSE, this brain
region could hypothetically also provide an invasion site for αSynPD pathology not only
after neural but possibly also after haematogenous spread. Although to the best of the
author’s knowledge there has been no evidence reported so far that αSynPD enters the
blood stream from GI tissue, such a scenario cannot be ruled out yet with absolute certainty.
Vagotomy and associated retrograde degeneration of DMV neurons could then theoretically
disrupt both parasympathetic and blood-borne neuroinvasion of the DMV. In this case,
demonstrating a protective effect of vagotomy on subsequent development of PD would
not be sufficient to prove that the vagus nerve is critically involved in the pathogenesis of
the disease.
5.2. Studies in Animals
Perorally acquired prion infections can be accurately modelled and studied in detail
in a variety of wild-type animal models, including rodents, ruminants and primates. For
PD, however, neither wild-type nor transgenic animal models accurately mimicking the
disease exist. While the causative neurotropic pathogens of TSE, prions, are considered
as reliably established, the situation with PD is substantially different. The identity of
the neurotropic pathogen in PD postulated by Braak and colleagues is unclear. If one
assumes this pathogen to be composed of prion-like αSynPD particles and sets aside the
open question of whether pathological forms of PD-associated αSyn are the causative
drivers of the disease at all, one faces the problem of how to test Braak’s concept on the
centripetal spread of LP in animal models none of which realistically replicates the disease.
Several different studies addressed this challenge by trying to trace the spread of αSyn
aggregates and αSyn pathology from the GI tract to the CNS. For this purpose, materials
containing pathological αSyn species from patients with α-synucleinopathies or in vitro
generated fibrillar or non-fibrillar αSyn assemblies, were injected into the stomach or gut
wall of laboratory animals as reviewed elsewhere [26,96]. While elegantly designed and
delivering important results, the actual probative value of these studies with respect to
Braak’s hypothesis on the gut–brain axis in PD is questionable.
First, non-PD αSyn species used in such tracing studies may not necessarily share the
structural and biological properties of αSynPD. Therefore, tracing results obtained with
aggregated αSyn species other than those from PD patients cannot be straightforwardly
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extrapolated to the postulated gut–brain axis in PD and are therefore not included in this
review. Second, tracing studies using authentic αSynPD species from PD patients have
not been performed in non-invasive ways as this was carried out by simple feeding of
prion-contaminated foodstuffs to study the spread of peroral TSE infections [46,48]. Rather,
inoculates containing αSynPD were administered by injection into the stomach and/or
intestinal wall [97,98].
One study by Holmqvist et al. [97] using invasive GI exposure of rodents to αSynPD
provided strong evidence that PD-associated αSyn aggregates injected into the intestinal
wall were transported retrogradely via the vagus nerve to the DMV. However, due to its
very design, this study was not able to do so for a natural route of exposure such as that
postulated by Braak and colleagues, and underlying peroral prion infections. Furthermore,
GI injection of tissue lysates or other materials containing αSynPD may result in an artificial
invasion of the blood stream and subsequent haematogenous spread to the brain with pos-
sible invasion of circumventricular organs and the DMV, as suggested by experiences from
the prion field. However, control experiments effectively ruling out such haematogenous
spread of their inoculums were not reported by the authors. This suggests to interpret the
detection of αSyn staining in the DMV by Holmqvist et al. only cautiously as evidence for
neural propagation along the vagus nerve. Irrespective of whether invasion of the DMV
in the rats of this study occurred via the vagus nerve or blood stream, it should be also
noted, as already suggested by Lionnet et al. [27], that there was no evidence for further
propagation of αSyn pathology in this brain region.
A second study addressing the spread of αSyn pathology after enteric injection
of αSynPD containing LB extracts from patients with PD was recently reported by
Arotcarena et al. [98]. These authors found in baboon monkeys indications for a bidirec-
tional spread via the blood circulation of pathological αSyn species between the ENS and
CNS. Notably, Arotcarena et al. did not find pathological αSyn lesions in the vagus nerve
or DMV and concluded that these neuroanatomical sites were not involved in the observed
spread of αSyn pathology in the used animal model. However, since the model animals
used in this study did not show any formation of LB or LN, even after intrastriatal injection
of αSynPD containing LB extracts, they do not seem to provide an ideal experimental
paradigm for testing Braak’s hypothesis on the vagal spread of LP. Rather, αSyn pathology
in this model was immunohistochemically characterized by pathological phosphorylation
of αSyn at serine 129 (pSer129 αSyn) and increased IHC staining intensities of pSer129
αSyn species in different brain regions, with the authors concluding cautiously that
“enteric injection of LB-enriched fractions might induce α-synuclein pathology throughout
the nigrostriatal tract, similar to that observed after striatal injection”.
Thus, taken together, the available data from animal studies do not support and
allow to delineate gut–brain spreading scenarios of αSynPD pathology as clearly as it has
been achieved for PrPTSE in peroral prion infections of animals. For this reason, Braak’s
hypothesis cannot be robustly validated based on the data from animal experiments
reported so far. Whether this will be possible in the future is a fundamental question
not only because of the lack of accurate animal PD models already mentioned above. To
date, stimulation of LP by injected αSynPD-containing inoculums has only been observed
in one animal study (in the form of LN) [99]. Otherwise, either only the induction of
diffuse pathological αSyn accumulations containing phosphorylated αSyn species [98,100]
or no αSyn pathology at all [101] have been detected in the brain of recipient animals
after enteric or intracerebral injection of such test materials. Furthermore, other than LB
extracts purified from postmortem PD brain tissue [100], peripheral αSynPD aggregates
prepared from sympathetic stellate ganglia of PD patients did not stimulate pSer129 αSyn
pathology after intracerebral injection into wildtype mice [102]. While the latter findings do
not necessarily challenge Braak’s hypothesis since the used mouse model did not develop
LB or LN at all and the injected peripheral αSynPD preparations had not been purified from
the ENS, they fit the notion that αSynPD seeds represent in several respects a much more
challenging subject for neuroanatomical tracing studies than PrPTSE of prion diseases.
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6. Conclusions
6.1. Does the Concept of a Neural Gut–Brain Axis of Pathological Protein Aggregation Hold in PD
and Which Alternative or Complementary Hypotheses Are Being Discussed?
The hypothesis of a neural gut–brain axis mediating stereotypical spread of patho-
logical prion-like protein aggregation in Parkinson’s disease, which originated from the
work of Braak and colleagues as referenced above, has undergone a remarkable devel-
opment in the past few years and triggered an ongoing multifaceted and controversial
discussion [27–29,74,96,103]. A comparison with its counterpart, the concept of a dual
neural gut–brain axis in peroral prion infections, shows that the robustness of the evidence
for centripetal spread of αSynPD or PrPTSE pathology along the gut–brain axis in PD and
peroral prion infections, respectively, is substantially stronger for the latter. As outlined,
this is due in large part to the disparity in the availability of non-invasive accurately
disease-mimicking animal models for detailed cause–effect studies on the spread of PrPTSE
and αSynPD pathology from the ENS to the brain.
The fact that research into the neural gut–brain axis of pathological protein aggregation
has faced and still faces much greater difficulties and challenges with respect to PD than it
did for peroral prion infections readily explains the limitations and shortcomings pointed
out above for pathophysiological PD studies conducted in this field. With the technology
where it is today, and when the data and their underlying studies presented in this review
are considered in their entity, this author feels it too early to judge whether the balance of
evidence and plausibility is more in favour of a neural gut–brain axis of spreading αSynPD
pathology in cases of PD than against it.
That said, this conclusion requires further consideration. Braak’s staging system of
LB pathology does not hold for all PD patients [26,104]. While this does not compromise
the staging system per se, it challenges its general validity for PD and that of the dual-hit
hypothesis postulating centripetal neural spread of LB pathology from the GI tract and
nasal cavity to initial target sites in the brain. It has been suggested that in some cases
of PD, the initial αSynPD pathology may occur in peripheral nerve terminals, whereas in
other cases, the formation and deposition of αSynPD starts in the brain [105]. Accordingly,
Borghammer et al. [88] proposed that PD can be possibly divided into a PNS-first and
a CNS-first subtype, depending on the location of the initial αSynPD pathology. If so,
the vagus nerve (and possibly also spinal-sympathetic projections) could theoretically
mediate both centripetal and centrifugal spread of αSynPD pathology to and from the brain,
respectively. Detection of αSynPD in peripheral tissues (e.g., the GI tract) would not then
necessarily indicate starting points of αSynPD pathology [105].
An alternative hypothesis proposed to explain apparently centripetal spreading pat-
terns of αSynPD pathology in PD holds that these could result from a “simultaneous and
concomitant susceptibility to disease mechanisms of neurons in both the CNS and the
ENS” [96]. In that case, LP and other αSynPD pathology would be governed by cell-
autonomous or regionally autonomous mechanisms [28], rather than by neurally spreading
αSynPD agents. In such a scenario, differences in the intrinsic cellular vulnerability for
αSynPD pathology would make specific populations of neurons less fit for αSynPD clear-
ance, or on the other hand, more susceptible to the formation of pathological αSyn aggre-
gates [26,106]. In this context, it has been suggested that if neural trans-synaptic spread of
αSynPD pathology along the gut–brain axis occurs in PD, it is gated, or modulated, by cell-
or regionally autonomous mechanisms [28] and is likely to provide only one of several
pathways possibly involved in the initiation and propagation of PD pathophysiology [105].
In any case, the unresolved challenges and open questions pointed out in this review
suggest caution with regard to definitive conclusions on the neural gut–brain axis of
pathological protein aggregation in PD and highlight the need to invest in further research
into this important topic. Several different approaches for this are outlined in the following.
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6.2. Possible Future Directions of Research
Animal models for PD available so far are not as realistic, powerful or robust as
those for perorally acquired TSE. The significantly lower transmission efficacy of aSynPD
seeds compared to prions substantially adds to this deficit. Thus, solid conclusions are
more difficult to draw from studies in animals on the neural gut–brain axis in PD than
in peroral prion infections. It remains to be seen whether further refined animal models
or experimental designs can overcome this fundamental problem in the future. However,
if animal studies will be used to further test Braak’s hypothesis on the gut–brain axis in
PD, it seems advisable to focus particularly on αSynPD from PD patients. For the reasons
outlined above, this seems to be more relevant and promising for the validation of the
hypothesis than, for example, studies with “synthetic” fibrillar or non-fibrillar aggregates
of recombinant αSyn, or with pathological αSyn species from patients with non-PD αSyn
aggregation diseases (e.g., DLB or MSA). Notwithstanding this, the latter approaches have
achieved important insights and may further do so in the future.
Prospectively, human organoids provide a complement or alternative to animal models
in studies on the neural gut–brain axis in PD. Human cerebral organoids have been recently
reported as a novel biological infection model for human prion diseases [107,108] and the
generation, from human pluripotent stem cells, of 3D neuromuscular organoids forming
functional neuromuscular junctions was described by Faustino Martins et al. [109]. If PD-
like αSyn aggregation could be seeded and propagated in neuro-intestinal or neuro-gastric
human organoids, this may open new avenues for research on PD as a whole, and the
neural gut–brain axis of the disease in particular.
Ideally, however, the trans-neuronal spreading proposed by Braak and others of
αSynPD pathology via neuroanatomical pathways of the autonomic nervous system from
the GI tract to the brain would be directly proven or rejected in humans. Important auxiliary
evidence in this context could be obtained from epidemiological analyses of whether
specific types of colectomies are associated with a reduced risk for the development
of PD [105]. Similarly, it would be interesting to investigate whether colonoscopy for
colorectal cancer screening, a preventive health measure in which persons with incipient
PD should not be statistically overrepresented, shows an association with PD [110]. This
could help to preventively address transfer risks and precautionary strategies with respect
to a theoretically conceivable transmission of αSynPD seeding activity from the ENS of
one person to that of another via endoscopes. At the same time, it might be also clarified
whether αSynPD seeds are being transmitted in this way in real life and subsequently
spread and act in recipients as would be expected according to Braak’s concept for such a
transfer scenario.
In addition to such epidemiological studies, novel lab analytical research approaches
for the examination of PD patients or biological sample materials from them might shed
further light on the neural gut–brain axis in PD. In vivo imaging using radiotracers and
positron emission tomography (PET) provided an innovative approach to demonstrate
a loss of sympathetic and parasympathetic nerve terminal function in Parkinson’s dis-
ease [111], but this examination method did not track αSynPD itself. Here, the development
of specific ligands for in vivo monitoring of the distribution of pathological αSynPD species
and its evolution over time, for example by longitudinal PET imaging, would provide a
further advanced but technically very challenging approach [27].
A quantitative mapping of the temporal–spatial course of the distribution of αSynPD
seeding activity in humans using highly sensitive real-time quaking induced conversion
(RT-QuIC) [112–115] or protein misfolding cyclic amplification (PMCA) [116] assays could
also provide important contributions to the elucidation of neuroanatomical spreading
pathways of αSyn pathology in PD. αSynPD seeding activity is assumed to constitute the
molecular driver underlying the propagation and spatial spread of pathological αSyn
aggregation in PD. As such, it appears as a fundamental and primary indicator for the
elucidation of αSynPD routing pathways covering both LP-associated as well as synaptic
αSynPD seeds. In principle, analyses on the distribution and spread of αSynPD seeding
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activity by RT-QuIC or PMCA should be feasible with cryopreserved postmortem tissue as
well as with tissue from living donors. Fixed tissue can be also analysed for αSynPD seeding
activity by RT-QuIC, but possibly with reduced sensitivity, as a recent report suggests [117].
Microdissection of specific tissue areas of interest could further refine such analyses.
In perorally acquired TSE initial peripheral neuroinvasion is thought to be essentially
mediated by spread of PrPTSE pathology from the gut-associated lymphoid tissue (GALT)
to the ENS [46,48], and the need for further investigating the involvement of the GALT
in PD pathogenesis has been recently highlighted, specifically with reference to prion
diseases [105]. Therefore, GALT specimens and other components of the lymphoretic-
ular system (LRS) from PD patients should be included in tracking studies for αSynPD
seeding activity.
By pursuing the suggested approach of RT-QuIC or PMCA analyses, snapshot rep-
resentations from postmortem tissues may allow for a systematic deconvolution of the
temporal–spatial course of the occurrence of seeding activity, and thus αSynPD seeds, in
different compartments of the gut–brain axis. Concomitantly, longitudinal studies on
the development of αSynPD pathology in the ENS could be performed in patients who
undergo regular gastroscopy or colonoscopy with biopsy sampling for disease monitoring
or treatment. This would possibly also help to settle the controversy on reports claiming the
detection of pathological αSynPD deposits in colonic and other gastro-intestinal biopsies
years before the onset of PD motor symptoms [27]. That detection of αSynPD seeding
activity by RT-QuIC assay in GI tissue from the stomach or colon of PD patients is feasible
has been recently demonstrated in two independent studies [99,115]. Thus, using the
relatively new and powerful analytical tools of RT-QuIC or PMCA for the quantitative
detection of αSynPD-associated seeding activity in human postmortem tissues and bioptic
samples may open new perspectives on both the neural gut–brain axis of pathological
protein aggregation and the ultrasensitive diagnostic detection of αSynPD seeds in PD.
Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Acknowledgments: The author thanks the Robert Koch Institute for excellent working conditions
over more than 25 years.
Conflicts of Interest: The author declares no conflict of interest.
References
1. Dickson, D.W. Parkinson’s disease and parkinsonism: Neuropathology. Cold Spring Harb. Perspect. Med. 2012, 2, a009258.
[CrossRef]
2. Schulz-Schaeffer, W.J. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease
and Parkinson’s disease dementia. Acta Neuropathol. 2010, 120, 131–143. [CrossRef]
3. Come, J.H.; Fraser, P.E.; Lansbury, P.T., Jr. A kinetic model for amyloid formation in the prion diseases: Importance of seeding.
Proc. Natl. Acad. Sci. USA 1993, 90, 5959–5963. [CrossRef] [PubMed]
4. Beekes, M.; Thomzig, A.; Schulz-Schaeffer, W.J.; Burger, R. Is there a risk of prion-like disease transmission by Alzheimer- or
Parkinson-associated protein particles? Acta Neuropathol. 2014, 128, 463–476. [CrossRef] [PubMed]
5. Oueslati, A.; Ximerakis, M.; Vekrellis, K. Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like
Propagation. Exp. Neurobiol. 2014, 23, 324–336. [CrossRef]
6. Melki, R. Alpha-synuclein and the prion hypothesis in Parkinson’s disease. Rev. Neurol. 2018, 174, 644–652. [CrossRef] [PubMed]
7. Baral, P.K.; Swayampakula, M.; Aguzzi, A.; James, M.N. X-ray structural and molecular dynamical studies of the globular
domains of cow, deer, elk and Syrian hamster prion proteins. J. Struct. Biol. 2015, 192, 37–47. [CrossRef] [PubMed]
8. Kraus, A.; Hoyt, F.; Schwartz, C.L.; Hansen, B.; Hughson, A.G.; Artikis, E.; Race, B.; Caughey, B. Structure of an infectious
mammalian prion. bioRxiv 2021. [CrossRef]
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